Conversion from mycophenolic acid to mizoribine in renal transplant recipients with gastrointestinal tract symptoms: a prospective observational multi-center study
- VernacularTitle:肾移植受者使用霉酚酸出现胃肠道症状时转换咪唑立宾治疗的多中心疗效观察研究
- Author:
Bingyi SHI
1
;
Jianxin QIU
;
Weiguo SUI
;
Jun TIAN
;
Youhua ZHU
;
Chunbo MO
;
Changxi WANG
;
Yingzi MING
;
Zhishui CHEN
;
Yaowen FU
;
Zheng CHEN
;
Longkai PENG
;
Zhilin HU
;
Tao LIN
;
Xuyong SUN
;
Hang LIU
;
Ruiming RONG
;
Ye TIAN
;
Wujun XUE
;
Ming ZHAO
;
Guiwen FENG
;
Ronghua CAO
;
Decheng DENG
;
Minzhuan LIN
;
Xiaodong ZHANG
Author Information
- Keywords: Renal transplantation; Mycophenolic Acid; Gastrointestinal tract symptoms; Mizoribine
- From: Chinese Journal of Organ Transplantation 2017;38(12):708-713
- CountryChina
- Language:Chinese
- Abstract: Objective To evaluate the effect of conversion from mycophenolic acid (MPA) to mizoribine (MZR) in renal transplant recipients with gastrointestinal tract (GI) symptoms.Methods A total of 355 renal transplant recipients with GI symptoms caused by MPA administration were enrolled from April 2015 to March 2017 in 25 different renal transplant centers in China.The symptomatic improvement of GI before (baseline) and after conversion to MZR (1,2,4 weeks) was assessed by each item of GI symptoms indication.In addition,the efficacy and safety of the conversion therapy during 12 months were determined.Results Patients showed improvement in GI symptoms including diarrhea,abdominal pain,abdominal distention and stomachache after conversion to MZR 1,2,4 weeks (P＜0.05).In patients with different severity of diarrhea,conversion to MZR therapy significantly improved diarrhea (P＜0.05).During 12 months,no patient experienced clinical immune rejection.We did not observe any infections,leucopenia and other serious side effects.Conclusion MZR could markedly improve GI symptoms caused by MPA administration in renal transplant recipients.
